MedTrace Logo

Efficacy of a Streamlined Heart Failure Optimization Protocol

NCT05021419 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-12

No results posted yet for this study

Summary

The SHORT trial compares the current standard optimization protocol to a shortened protocol in a randomized control trial.

Conditions

Interventions

OTHER

Streamlined protocol

A streamlined drug protocol for optimizing heart failure medication

OTHER

Standard Protocol

Current standard optimization protocol as per NICE and ESC

Sponsors & Collaborators

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Rudolf M Duehmke, BSc MBBS PhD · The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-17
Primary Completion
2024-01-07
Completion
2024-01-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05021419 on ClinicalTrials.gov